SPN-820 was well-tolerated with few adverse events. Earlier this month, the FDA approved Supernus Pharmaceuticals’ ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830 ...

Earlier this month, the FDA approved ONAPGO Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...

Earlier this month, the FDA approved ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...

JonesResearch analyst Justin Walsh initiated coverage of Serina Therapeutics (SER) with a Buy rating and $11 price target. Serina is a drug ...

President and CEO of Supernus. "In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson's disease, planned for the second quarter of 2025; and further ...

The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...

President and CEO of Supernus. "In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson's disease, planned for the second quarter of 2025; and further ...

Supernus also announced FDA approval for ONAPGO, its treatment for motor fluctuations in adults with advanced Parkinson's disease. The company plans to launch ONAPGO in the second quarter of 2025.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced ...

Supernus Pharmaceuticals is a biopharmaceutical company focused ... the Company's ability to commercialize its products and the products of its subsidiaries including ONAPGO; the Company's ability to ...